ALPS Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.44M | Buy |
4,917
+2,649
| +117% | +$1.17M | 0.01% | 459 |
|
|
2026
Q1 | $1.01M | Sell |
2,268
-230
| -9% | -$107K | ﹤0.01% | 583 |
|
|
2025
Q4 | $1.13M | Buy |
2,498
+99
| +4% | +$42.7K | 0.01% | 527 |
|
|
2025
Q3 | $940K | Buy |
2,399
+1,160
| +94% | +$485K | 0.01% | 520 |
|
|
2025
Q2 | $552K | Sell |
1,239
-78
| -6% | -$35.9K | ﹤0.01% | 612 |
|
|
2025
Q1 | $639K | Buy |
1,317
+529
| +67% | +$247K | ﹤0.01% | 555 |
|
|
2024
Q4 | $317K | Sell |
788
-17
| -2% | -$7.88K | ﹤0.01% | 857 |
|
|
2024
Q3 | $374K | Sell |
805
-1,327
| -62% | -$637K | ﹤0.01% | 718 |
|
|
2024
Q2 | $999K | Buy |
2,132
+80
| +4% | +$34.7K | 0.01% | 463 |
|
|
2024
Q1 | $858K | Sell |
2,052
-291
| -12% | -$123K | 0.01% | 519 |
|
|
2023
Q4 | $953K | Sell |
2,343
-311
| -12% | -$115K | 0.01% | 492 |
|
|
2023
Q3 | $923K | Buy |
2,654
+183
| +7% | +$64K | 0.01% | 484 |
|
|
2023
Q2 | $870K | Buy |
2,471
+839
| +51% | +$283K | 0.01% | 520 |
|
|
2023
Q1 | $514K | Sell |
1,632
-995
| -38% | -$298K | ﹤0.01% | 589 |
|
|
2022
Q4 | $759K | Sell |
2,627
-120
| -4% | -$36.6K | 0.01% | 525 |
|
|
2022
Q3 | $795K | Buy |
2,747
+411
| +18% | +$118K | 0.01% | 514 |
|
|
2022
Q2 | $658K | Buy |
2,336
+97
| +4% | +$26K | 0.01% | 535 |
|
|
2022
Q1 | $584K | Sell |
2,239
-792
| -26% | -$188K | 0.01% | 412 |
|
|
2021
Q4 | $666K | Sell |
3,031
-354
| -10% | -$68.8K | 0.01% | 451 |
|
|
2021
Q3 | $614K | Buy |
3,385
+1,614
| +91% | +$315K | 0.01% | 474 |
|
|
2021
Q2 | $357K | Sell |
1,771
-63
| -3% | -$13.2K | ﹤0.01% | 673 |
|
|
2021
Q1 | $394K | Sell |
1,834
-1,432
| -44% | -$315K | ﹤0.01% | 518 |
|
|
2020
Q4 | $772K | Sell |
3,266
-272
| -8% | -$62.4K | 0.01% | 417 |
|
|
2020
Q3 | $963K | Buy |
3,538
+1,323
| +60% | +$365K | 0.01% | 358 |
|
|
2020
Q2 | $643K | Buy |
2,215
+1,149
| +108% | +$312K | 0.01% | 411 |
|
|
2020
Q1 | $254K | Sell |
1,066
-921
| -46% | -$211K | ﹤0.01% | 557 |
|
|
2019
Q4 | $435K | Sell |
1,987
-87
| -4% | -$17.6K | ﹤0.01% | 532 |
|
|
2019
Q3 | $351K | Sell |
2,074
-21
| -1% | -$3.71K | ﹤0.01% | 742 |
|
|
2019
Q2 | $384K | Sell |
2,095
-112
| -5% | -$19.6K | ﹤0.01% | 685 |
|
|
2019
Q1 | $406K | Buy |
+2,207
| New | +$408K | ﹤0.01% | 670 |
|
Other funds holding VRTX
ALPS Advisors's VRTX Position: Q2 2026 in Review
ALPS Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 117% in Q2 2026, buying an estimated $1.17M and bringing the position to 4,917 shares worth $2.44M. The position accounts for 0.01% of the portfolio, ranked #459.
ALPS Advisors first reported a position in VRTX in Q1 2019 and has held it in 30 quarters since. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- ALPS Advisors held 4,917 shares of Vertex Pharmaceuticals worth $2.44M as of Q2 2026.
- ALPS Advisors bought 2,649 Vertex Pharmaceuticals shares in Q2 2026, an estimated $1.17M.
- Vertex Pharmaceuticals made up 0.01% of ALPS Advisors's portfolio in Q2 2026, its #459 holding.
- ALPS Advisors first reported a position in Vertex Pharmaceuticals in Q1 2019 and has held it in 30 quarters since.
- 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on ALPS Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.